Releases Details
Director/PCA transaction initial notification
Released : December 16, 2019 17:25
MaxCyte, Inc.
("MaxCyte" or the "Company")
Director/PCA transaction initial notification
Following the transaction, the number of shares in which John Johnston has an interest remains unchanged at 120,583 Ordinary Shares.
This announcement, including the notification below, is made in accordance with the requirements of Article 7 of Regulation (EU) No 596/2014 ("MAR").
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
|
1 |
Details of the person discharging managerial responsibilities/person closely associated |
||
|
a) |
Name |
John Johnston |
|
|
2 |
Reason for the notification |
||
|
a) |
Position/status |
Non-Executive Director and PDMR |
|
|
b) |
Initial notification/Amendment |
Initial notification |
|
|
3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||
|
a) |
Name |
MaxCyte, Inc. |
|
|
b) |
LEI |
|
|
|
4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||
|
a) |
Description of the financial instrument, type of instrument |
Ordinary shares |
|
|
b) |
Identification Code |
|
|
|
c) |
Nature of the transaction |
Transfer of Ordinary Shares to spouse/PCA |
|
|
d) |
Price(s) and volume(s) |
Price(s) |
Volume(s) |
|
|
|
||
|
e) |
Aggregated information - Aggregated volume - Price |
N/A 17,041 |
|
|
f) |
Date of the transaction |
14 December 2019 |
|
|
g) |
Place of the transaction |
London Stock Exchange, AIM Market (XLON) |
|
For further information, please contact:
|
MaxCyte Inc. |
|
|
Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Financial Officer |
+1 301 944 1660 |
|
Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl Freddy Crossley Corporate Broking James Stearns
|
+44 (0)20 7886 2500 |
|
Joint Corporate Broker Numis Securities Limited James Black Duncan Monteith |
+44 (0)20 7260 1000 |
|
Financial PR Adviser Consilium Strategic Communications |
|
|
Mary-Jane Elliott Chris Welsh Sukaina Virji
|
+44 (0)203 709 5700 |
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life sciences company applying its proprietary cell engineering platform to deliver the advances of cell-based medicine to patients with high unmet medical needs. MaxCyte is developing novel CARMA therapies for its own pipeline, with its first drug candidate in a Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary therapeutic platform for autologous cell therapy for the treatment of solid cancers. In addition, through its life sciences business, MaxCyte leverages its Flow Electroporation Technology to enable its biopharmaceutical partners to advance the development of innovative medicines, particularly in cell therapy. MaxCyte has placed its flow electroporation instruments worldwide, including with all of the top ten global biopharmaceutical companies. The Company now has more than 80 partnered programme licenses in cell therapy with more than 45 licensed for clinical use, including five commercial licenses. Aggregate potential pre-commercial milestones from all license deals total more than
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the
